Stavudine (d4T, Zerit)

The Latest

Ending Global Use of d4T: UNITAID to Tip Market to Safer Alternatives

On 11 June 2013, UNITAID announced in a press statement that it was committing USD $77 million to end of the use of the archaic HIV drug d4T (stavudine) and replace it with tenofovir which is a newer more effective alternative.1

Although d4T was wid...

By Simon Collins for HIV i-Base

d4T -- Time to Move On

The first conference of the Southern African Clinician's Society1 burst into life with a demonstration by the Treatment Action Campaign (TAC).

TAC were unequivocal that repurposing d4T at any dose is not an acceptable way to conquer cost concerns wi...

By Polly Clayden for HIV i-Base

High Prevalence of d4T-Associated Lipodystrophy Including Lipoatrophy in Children

Data describing lipodystrophy in children from sub-Saharan Africa are extremely limited. However use of d4T is widespread among children receiving ART in the region: in 2008 to 2009 approximately 90% of children on ART were taking d4T.

Two posters a...

By Polly Clayden for HIV i-Base

New Labeling for Zerit Capsules and Zerit for Oral Solution

On December 10, 2010, the FDA approved new labeling for Zerit capsules and Zerit for oral solution. The revisions to the Dosage and Administration, Warnings and Precautions, Adverse Reaction sections in both package inserts are outlined below.


By U.S. Food and Drug Administration

Both Tenofovir and Stavudine Well Tolerated in HCV-Coinfected Patients

The Gilead 903 study was an open-label, randomized clinical trial that compared tenofovir (TDF, Viread) with stavudine (d4T, Zerit). All of the patients in that study also received lamivudine (3TC, Epivir) and efavirenz (EFV, Sustiva, Stocrin). As ha...

By Paul E. Sax, M.D.

Predicting Lipoatrophy After Treatment Initiation

I liked this study. Mustafa Noor and the Bristol-Myers Squibb (BMS) group did a post-hoc analysis of a recent, large, randomized trial that compared the use of the currently available formulation of stavudine (d4T, Zerit) and stavudine extended relea...

By Pablo Tebas, M.D.

A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir

Controversy still exists regarding which is the best antiretroviral therapy (ART) to start with. We all agree that the regimen must be potent, safe, well tolerated, convenient for the individual, and must demonstrate both efficacy and durability.


By Judith A. Aberg, M.D., F.I.D.S.A.

South African Generic Drug Maker to Produce Country's First Generic Antiretroviral Drug

Aspen Pharmacare, southern Africa's largest generic drug manufacturer, yesterday announced that it will develop and produce the continent's first generic antiretroviral drug, called Aspen-Stavudine, South Africa's Mail & Guardian reports (Mail & Guar...

By Henry J. Kaiser Family Foundation

Forty-Eight Week Data From FTC-d4T Comparison in Treatment-Naive Patients

A Randomized, Double-Blind, Multicenter Comparison of Emtricitabine QD to Stavudine BID in Treatment-Naive HIV-Infected Patients (Oral 38) Authored by F. Raffi, M. Saag, P. Cahn, M. Wolff, D. Pearce, J.M. Molina, J. Hinkle, A. Shaw, E. Mondou, ...

By Paul E. Sax, M.D.

Trizivir Causes Lowest Triglycerides Rise in Comparison With Combivir + Nelfinavir or d4T

Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Trizivir (TZV), Combivir (COM)/Nelfinavir (NFV), or Stavudine (d4T)/Lamivudine (3TC)/NFV (Poster 709) Authored by P. Kumar, A. Rodriguez-French, M. Thompson, K. Tashima, P. Wannam...

By Timothy Wilkin, M.D., M.P.H.